Validation Data Gallery
Tested Applications
Recommended dilution
| Application | Dilution |
|---|---|
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Product Information
32103-1-PBS targets BCL9L in WB, IF/ICC, Indirect ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag36794 Product name: Recombinant human BCL9L protein Source: e coli.-derived, PGEX-4T Tag: GST Domain: 38-206 aa of NM_182557 Sequence: MHPENKLTNHGKTGNGGAQSQHQNVNQGPTCNVGSKGVGAGNHGAKANQISPSNSSLKNPQAGVPPFSSLKGKVKRDRSVSVDSGEQREAGTPSLDSEAKEVAPRSKRRCVLERKQPYSGDEWCSGPDSEEDDKPIGATHNCNVADPAMAAPQLGPGQTTQLPLSESSV 相同性解析による交差性が予測される生物種 |
| Full Name | B-cell CLL/lymphoma 9-like |
| Calculated molecular weight | 157 kDa |
| Observed molecular weight | 220 kDa |
| GenBank accession number | NM_182557 |
| Gene Symbol | BCL9L |
| Gene ID (NCBI) | 283149 |
| Conjugate | Unconjugated |
| Form | |
| Form | Liquid |
| Purification Method | Antigen affinity Purification |
| UNIPROT ID | Q86UU0 |
| Storage Buffer | PBS only{{ptg:BufferTemp}}7.3 |
| Storage Conditions | Store at -80°C. |
Background Information
B-cell CLL/lymphoma 9-like protein (BCL9L, also known as B9L, BCL9-2, and DLNB11) is a transcriptional regulator that acts as an activator, which locates in nucleolus and nucleoplasm (PMID: 33767438). It is predicted to be implicated in the WNT-β-catenin signaling pathway to regulate the progress of hepatocellular carcinoma, breast cancer, and colon cancer (PMID: 31440992; 34545187; 30698996).

